Compare BridgeBio Pharma Inc (BBIO) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Texas Instruments Incorporated — how do they compare? BridgeBio Pharma Inc trades at $82.37 (market cap $16.46B), while Texas Instruments Incorporated trades at $296.34 (market cap $278.08B). The key difference: Texas Instruments Incorporated is far larger — about 16.9× BridgeBio Pharma Inc's market cap, and Texas Instruments Incorporated pays a 1.86% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | TXN | |
|---|---|---|
Market Cap | $16.46B | $278.08B |
Sector | Health | Technology |
52-Week High | $90.17 | $332.35 |
52-Week Low | $44.81 | $153.33 |
Enterprise Value | $18.02B | $287.03B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Texas Instruments (TXN) trades at $298.57, down 4.15% over the past day, with technical indicators showing a bearish trend. The company reported mixed earnings, missing estimates in Q3 and Q4 2025 but beating in Q1 2026, with revenue of $17.68 billion in 2025. Analyst sentiment is positive, with a consensus price target of $317.20 and 48% buy ratings. Recent news highlights a CFO transition and strong AI-driven demand in data centers.
Outlook: TXN benefits from AI infrastructure growth and operational leverage, but faces risks from high valuation multiples and competitive pressures. The stock offers potential upside to the consensus target, supported by solid profitability and dividend payments, though investors should monitor debt levels and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
